Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 10 Other solid neoplasm 8 Gynecologic 7 Other hematologic neoplasm 5 Tumor-Agnostic 4 Thoracic 4 Genitourinary 4 Gastrointestinal 4 Myeloid 2 Sarcoma 1 NET 1 Lymphoid 1 Head & Neck 1 Endocrine 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 10 lutetium Lu 177 dotatate 7 Magnetic Resonance Spectroscopy 7 pasireotide 4 Specimen Handling 3 Positron Emission Tomography Computed Tomography 3 Nivolumab 3 Ga(III)-DOTATOC 3 Fluorodeoxyglucose F18 3 (177)Lu-DOTA-EB-TATE 3 olaparib 2 gallium Ga 68 dotatate 2 amino-acid, glucose, and electrolyte solution 2 Temozolomide 2 Lutetium-177 2 Ipilimumab 2 FAPI-46 2 veliparib 1 vandetanib 1 trifluridine tipiracil drug combination 1 toripalimab 1 tislelizumab 1 talazoparib 1 surufatinib 1 romidepsin 1 peposertib 1 pembrolizumab 1 pelcitoclax 1 pegfilgrastim 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × talazoparib × NET × Clear all

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡